Clinical Trial

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to see if giving reduced intensity chemotherapy, haploidentical bone marrow, post-transplant cyclophosphamide and shortened duration tacrolimus is safe and feasible for patients with very high-risk solid tumors.
Protocol Amendment History 19 amendments
This ClinicalTrials.gov record has been amended 19 times since 2013-03-01; most recent amendment 2026-03-11.
Trial Details
NCT Number NCT01804634
Lead Sponsor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators: National Cancer Institute (NCI)
Conditions Refractory and/or Relapsed Metastatic Solid Tumors
Enrollment 60 participants
Start Date 2013-03-27
Primary Completion 2027-01 (estimated)
Study Completion 2030-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-13